J7513Drugs Administered Other than Oral Method

Daclizumab, parenteral, 25 mg

Short description: Daclizumab, parenteral

Effective date: January 1, 2026
Termination date: —

Related codes (J-series)

J0013Esketamine, nasal spray J0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injection J0121Inj., omadacycline, 1 mg J0122Inj., eravacycline, 1 mg J0129Abatacept injection J0130Abciximab injection J0131Inj, acetaminophen (nos)J0132Acetylcysteine injection J0133Acyclovir injection J0134Inj acetaminophen -fresenius J0135Adalimumab injection

Frequently asked questions

What is HCPCS code J7513?

J7513 is a HCPCS Level II code for Daclizumab, parenteral, 25 mg.

What category is HCPCS code J7513 in?

J7513 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.

When did HCPCS code J7513 become effective?

J7513 has been effective since January 1, 2026, per CMS's quarterly HCPCS update.

HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.